Research progress of non-coding RNA in gastrointestinal stromal tumor
10.3969/j.issn.1007-3969.2015.05.013
- VernacularTitle:非编码RNA在胃肠间质瘤中的研究进展
- Author:
Chunmeng WANG
;
Jie CHEN
;
Yingqiang SHI
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stromal tumor;
Imatinib mesylate;
Non-coding RNA
- From:
China Oncology
2015;(5):392-396
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal mesenchymal tumors, mainly due to the onset of the proto-oncogene receptor tyrosine kinase, or platelet-derived growth factor receptor gene activating mutations. Molecular targeted therapy drug of imatinib mesylate inhibit KIT, platelet-derived growth factor receptor aloha (PDGFRA) gene tyrosine kinase activity, which is effective in patients with advanced GIST. However, a growing number of studies have found the presence of imatinib mesylate in primary and secondary drug resistance in the treatment of GIST process. With the in-depth study of the physiological function and mechanism of action of non-coding RNA in recent years, making it gradually realized extensive regulation of non-coding RNA gene expression, which occurs in tumor development, invasion and metastasis, drug resistance and other processes plays an important role. Non-coding RNA has the potential to explore GIST pathogenesis and resistance mechanisms to provide new ideas and direction.
